The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For the first time in humans, a chemotherapy drug reaches the brain.

2.

unhealthy sleeping habits and the risk of esophageal adenocarcinoma.

3.

FDA Expands Durvalumab Label to Operable Lung Cancer

4.

Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

5.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot